Blueprint Medicines (NASDAQ: BPMC)
Blueprint Medicines Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Blueprint Medicines Company Info
Blueprint Medicines Corp. is a precision therapy company, which engages in the invention of medicines for people with cancer and blood disorders. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy on October 14, 2008 and is headquartered in Cambridge, MA.
News & Analysis
Why Blueprint Medicines Stock Soared Today
The precision-treatment company saw stronger-than-expected sales in its first full quarter following the launch of Ayvakit.
Why Shares of Blueprint Medicines Are Falling Wednesday
The company had generally improved earnings.
This Biotech Could Soon Go Parabolic, But Should You Buy It?
Its situation is neither as good nor as bad as it might seem at first glance.
2 Under-the-Radar Biotech Stocks to Buy in 2022
Both companies have catalysts for explosive growth this year.
1 Cancer Stock to Buy and Hold for the Next Decade
Blueprint Medicines is setting itself up to become the leader in precision oncology.
Is Blueprint Medicines a Good Biotech Stock to Buy Now?
Here's what investors need to know about this successful yet underappreciated cancer drug developer.
Blueprint Medicines Inks Deal With Roche Worth Up to $1.7 Billion
Roche is licensing commercial rights to Blueprint Medicines RET-inhibitor pralsetinib.
The Debate Is Over: This Cancer Stock Is Winning the GIST Race
Blueprint Medicines and Deciphera Pharmaceuticals were going toe-to-toe developing treatments for this rare cancer. Investors can now call the winner.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.